000309945 001__ 309945
000309945 005__ 20260220120944.0
000309945 0247_ $$2doi$$a10.3389/fonc.2026.1700649
000309945 0247_ $$2pmid$$apmid:41710668
000309945 0247_ $$2pmc$$apmc:PMC12909239
000309945 037__ $$aDKFZ-2026-00394
000309945 041__ $$aEnglish
000309945 082__ $$a610
000309945 1001_ $$0P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aWeykamp, Fabian$$b0$$eFirst author$$udkfz
000309945 245__ $$aLong-term patient experience with online MR-guided radiotherapy: adaptive versus non-adaptive workflow.
000309945 260__ $$aLausanne$$bFrontiers Media$$c2026
000309945 3367_ $$2DRIVER$$aarticle
000309945 3367_ $$2DataCite$$aOutput Types/Journal article
000309945 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771510162_3004203
000309945 3367_ $$2BibTeX$$aARTICLE
000309945 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309945 3367_ $$00$$2EndNote$$aJournal Article
000309945 500__ $$a#EA:E050#LA:E050# / #DKTKZFB26# / #NCTZFB26#
000309945 520__ $$aMagnetic resonance-linear accelerator (MR-Linac) systems enable high-precision radiotherapy through real-time MR guidance and daily online adaptive treatment planning. While online adaptation offers substantial dosimetric advantages, it extends treatment session durations on an already resource-intensive platform. This study aimed to evaluate patient-reported outcome measures (PROMs) and long-term toxicity profiles associated with MR-guided radiotherapy, with a particular focus on the impact of online adaptive workflows.This subgroup analysis of an ongoing prospective observational study comprises patients treated with the MRIdian Linac at the Department of Radiation Oncology at Heidelberg University Hospital between January 2019 and May 2021. Online plan adaptation was implemented in February 2020. A custom-designed in-house questionnaire (PRO-Q) was employed to assess patient experience with MR-guided treatment. Toxicity was classified according to the Common Terminology Criteria for Adverse Events (CTCAE v. 5.0).A total of 231 patients were included, comprising 130 non-adaptive and 101 adaptive treatments across 286 target volumes. Baseline patient characteristics, prior systemic therapy, and median planning target volumes (36.4 mL vs. 35.3 mL) were comparable between groups. Adaptive treatment was associated with significantly prolonged session durations (median 71 minutes vs. 36 minutes; p<0.01). During adaptive treatment, patients reported significantly higher discomfort in domains related to treatment duration, immobility, and sensory perceptions (e.g., tingling) as per PRO-Q responses. No statistically significant differences in overall toxicity were observed. However, patients undergoing adaptive therapy exhibited a faster return to baseline status post-treatment (6-8 weeks vs. 6-12 months).Online plan adaptation at the MR-Linac increased treatment times and was associated with less favorable short-term patient-reported outcomes, yet it was delivered safely without compromising toxicity or oncologic outcomes. These results support adaptive MR-guided radiotherapy as a feasible and technically promising approach, while highlighting the need for further studies with validated PROMs and cost-benefit analyses to define its clinical value.
000309945 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000309945 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309945 650_7 $$2Other$$aMR-guided
000309945 650_7 $$2Other$$aadaptive radiotherapy
000309945 650_7 $$2Other$$alocal control (LC)
000309945 650_7 $$2Other$$apatient-reported outcomes
000309945 650_7 $$2Other$$astereotactic body radiotherapy (SBRT)
000309945 7001_ $$aHerder-Wagner, Charlotte$$b1
000309945 7001_ $$0P:(DE-He78)f4c0be14a7bb58948e5800ccdcbfe9bc$$aRegnery, Sebastian$$b2$$udkfz
000309945 7001_ $$0P:(DE-HGF)0$$aLiermann, Jakob$$b3
000309945 7001_ $$0P:(DE-HGF)0$$aMeixner, Eva$$b4
000309945 7001_ $$0P:(DE-HGF)0$$aHoegen-Saßmannshausen, Philipp$$b5
000309945 7001_ $$0P:(DE-HGF)0$$aKönig, Laila$$b6
000309945 7001_ $$0P:(DE-HGF)0$$aLang, Kristin$$b7
000309945 7001_ $$0P:(DE-HGF)0$$aRenkamp, C Katharina$$b8
000309945 7001_ $$0P:(DE-He78)5d2f4f57d14e838a6cfee15e3ad38856$$aRippke, Carolin$$b9
000309945 7001_ $$0P:(DE-HGF)0$$aKlüter, Sebastian$$b10
000309945 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b11$$udkfz
000309945 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b12$$eLast author$$udkfz
000309945 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2026.1700649$$gVol. 16, p. 1700649$$p1700649$$tFrontiers in oncology$$v16$$x2234-943X$$y2026
000309945 909CO $$ooai:inrepo02.dkfz.de:309945$$pVDB
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4c0be14a7bb58948e5800ccdcbfe9bc$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5d2f4f57d14e838a6cfee15e3ad38856$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000309945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000309945 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000309945 9141_ $$y2026
000309945 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2022$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2025-05-13T11:24:55Z
000309945 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2025-05-13T11:24:55Z
000309945 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2025-05-13T11:24:55Z
000309945 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2025-05-13T11:24:55Z
000309945 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-11
000309945 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-11
000309945 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000309945 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000309945 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000309945 9201_ $$0I:(DE-He78)HD02-20160331$$kHD02$$lKoordinierungsstelle NCT Heidelberg$$x2
000309945 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000309945 980__ $$ajournal
000309945 980__ $$aVDB
000309945 980__ $$aI:(DE-He78)E050-20160331
000309945 980__ $$aI:(DE-He78)HD01-20160331
000309945 980__ $$aI:(DE-He78)HD02-20160331
000309945 980__ $$aUNRESTRICTED